# Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

> **NCT01215578** · PHASE2 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 33 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Pancreatic Neoplasms
- Advanced Disease
- Sunitinib

## Interventions

- **DRUG:** Sutent

## Key facts

- **NCT ID:** NCT01215578
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** lack of recruitement
- **Last updated:** 2015-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215578, "Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01215578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*